Tags

Type your tag names separated by a space and hit enter

Effects of selenium status and polymorphisms in selenoprotein genes on prostate cancer risk in a prospective study of European men.

Abstract

BACKGROUND

Evidence for an association between selenium status and prostate cancer risk is still inconclusive. Anticarcinogenic effects of selenium are supposedly mediated through cellular protective and redox properties of selenoenzymes in vivo. We evaluated the association between serum selenium status and prostate cancer risk in a population with relative low selenium concentrations considering effect modification by genetic variants in selenoprotein genes.

MATERIALS AND METHODS

A case-control study of 248 incident prostate cancer cases and 492 matched controls was nested within the EPIC-Heidelberg cohort. Baseline blood samples were analyzed for serum selenium and selenoprotein P concentrations and glutathione peroxidase activity. Genotyping was carried out for SEP15 (rs5859, rs540049), SEPP1 (rs3877899, rs7579), GPX1 (rs1050450), and GPX4 (rs713041). Conditional logistic regression was used to calculate adjusted odds ratios (OR) and 95% confidence intervals (95% CI).

RESULTS

The OR for prostate cancer was 0.89 (95% CI, 0.79-1.01) per 10 μg/L increase of serum selenium concentration. This association was modified by rs1050450 (C>T) in GPX1 (P(interaction) = 0.03), with carriers of one or two T alleles having a significantly reduced OR of 0.87 (95% CI, 0.76-0.99). Furthermore, there was an association between rs7579 genotype in SEPP1 and prostate cancer risk (OR, 1.72; 95% CI, 0.99-2.98).

CONCLUSIONS

Our results support a role of selenium and polymorphisms in selenoenzymes in prostate cancer etiology, which warrants confirmation in future studies.

IMPACT

These findings might help to explain biological effects of selenium in prostate cancer development in order to overcome inconsistencies arising from former studies.

Links

  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.

    , , , , , , ,

    Source

    MeSH

    Adult
    Case-Control Studies
    Europe
    Genetic Predisposition to Disease
    Genotype
    Glutathione Peroxidase
    Humans
    Male
    Middle Aged
    Odds Ratio
    Polymorphism, Single Nucleotide
    Prostatic Neoplasms
    Risk Factors
    Selenium
    Selenoproteins
    Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

    Pub Type(s)

    Journal Article
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    20852007

    Citation

    Steinbrecher, Astrid, et al. "Effects of Selenium Status and Polymorphisms in Selenoprotein Genes On Prostate Cancer Risk in a Prospective Study of European Men." Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, vol. 19, no. 11, 2010, pp. 2958-68.
    Steinbrecher A, Méplan C, Hesketh J, et al. Effects of selenium status and polymorphisms in selenoprotein genes on prostate cancer risk in a prospective study of European men. Cancer Epidemiol Biomarkers Prev. 2010;19(11):2958-68.
    Steinbrecher, A., Méplan, C., Hesketh, J., Schomburg, L., Endermann, T., Jansen, E., ... Linseisen, J. (2010). Effects of selenium status and polymorphisms in selenoprotein genes on prostate cancer risk in a prospective study of European men. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, 19(11), pp. 2958-68. doi:10.1158/1055-9965.EPI-10-0364.
    Steinbrecher A, et al. Effects of Selenium Status and Polymorphisms in Selenoprotein Genes On Prostate Cancer Risk in a Prospective Study of European Men. Cancer Epidemiol Biomarkers Prev. 2010;19(11):2958-68. PubMed PMID: 20852007.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Effects of selenium status and polymorphisms in selenoprotein genes on prostate cancer risk in a prospective study of European men. AU - Steinbrecher,Astrid, AU - Méplan,Catherine, AU - Hesketh,John, AU - Schomburg,Lutz, AU - Endermann,Tobias, AU - Jansen,Eugène, AU - Akesson,Björn, AU - Rohrmann,Sabine, AU - Linseisen,Jakob, Y1 - 2010/09/17/ PY - 2010/9/21/entrez PY - 2010/9/21/pubmed PY - 2011/2/23/medline SP - 2958 EP - 68 JF - Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology JO - Cancer Epidemiol. Biomarkers Prev. VL - 19 IS - 11 N2 - BACKGROUND: Evidence for an association between selenium status and prostate cancer risk is still inconclusive. Anticarcinogenic effects of selenium are supposedly mediated through cellular protective and redox properties of selenoenzymes in vivo. We evaluated the association between serum selenium status and prostate cancer risk in a population with relative low selenium concentrations considering effect modification by genetic variants in selenoprotein genes. MATERIALS AND METHODS: A case-control study of 248 incident prostate cancer cases and 492 matched controls was nested within the EPIC-Heidelberg cohort. Baseline blood samples were analyzed for serum selenium and selenoprotein P concentrations and glutathione peroxidase activity. Genotyping was carried out for SEP15 (rs5859, rs540049), SEPP1 (rs3877899, rs7579), GPX1 (rs1050450), and GPX4 (rs713041). Conditional logistic regression was used to calculate adjusted odds ratios (OR) and 95% confidence intervals (95% CI). RESULTS: The OR for prostate cancer was 0.89 (95% CI, 0.79-1.01) per 10 μg/L increase of serum selenium concentration. This association was modified by rs1050450 (C>T) in GPX1 (P(interaction) = 0.03), with carriers of one or two T alleles having a significantly reduced OR of 0.87 (95% CI, 0.76-0.99). Furthermore, there was an association between rs7579 genotype in SEPP1 and prostate cancer risk (OR, 1.72; 95% CI, 0.99-2.98). CONCLUSIONS: Our results support a role of selenium and polymorphisms in selenoenzymes in prostate cancer etiology, which warrants confirmation in future studies. IMPACT: These findings might help to explain biological effects of selenium in prostate cancer development in order to overcome inconsistencies arising from former studies. SN - 1538-7755 UR - https://www.unboundmedicine.com/medline/citation/20852007/Effects_of_selenium_status_and_polymorphisms_in_selenoprotein_genes_on_prostate_cancer_risk_in_a_prospective_study_of_European_men_ L2 - http://cebp.aacrjournals.org/cgi/pmidlookup?view=long&pmid=20852007 DB - PRIME DP - Unbound Medicine ER -